Increased Scrutiny of Psychedelics Market

There is some evidence of negative investor sentiment toward a psychedelics-focused biotech (Cybin) tied to healthcare uncertainty, which weakly supports the thesis, but none of the articles specifically tie back to the original MDMA-therapy takeover controversy or show clear regulatory/policy action. Most articles are about unrelated pharma topics (drug pricing, M&A, national security reviews), making the evidence too diffuse to confirm or clearly falsify the prediction.